Dale, J., and Porter, D. (2010) Optimising the strategy of care in early rheumatoid arthritis. Best Practice and Research: Clinical Rheumatology, 24 (4). pp. 443-455. ISSN 1521-6942 (doi:10.1016/j.berh.2009.11.009)
Full text not currently available from Enlighten.
Publisher's URL: http://dx.doi.org/10.1016/j.berh.2009.11.009
In rheumatoid arthritis (RA), early use of disease-modifying antirheumatic drugs (DMARDs), intensive follow-up and 'treating to target' to achieve low disease activity produce significant improvements in measures of disease activity, functional impairment and retard erosive radiographic progression. Step-up, parallel and step-down regimens are all significantly more effective than sequential monotherapy; although the most effective regimen has not been established. Minimising the period of exposure to synovitis, by including a rapidly acting agent (e.g., corticosteroids or tumour necrosis factor cc (TNF alpha) inhibitor), may slow radiographic progression further. Biologic therapies, especially TNF alpha inhibitors, are effective in early RA; however, their exact role is unclear. Current measures may overestimate the number of patients in clinical remission; therefore, musculoskeletal ultrasound and/or novel biomarkers may also have a role. Pre-clinical immunological markers could possibly be used to trigger pre-emptive treatment in asymptomatic, 'at risk' individuals. Potential treatment developments include combining biologic agents or targeting alternative immunological pathways.
|Glasgow Author(s):||Porter, Dr Duncan and Dale, Dr James|
|Authors:||Dale, J., and Porter, D.|
|College/School:||College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation > Immunology|
|Journal Name:||Best Practice and Research: Clinical Rheumatology|